[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fumYfGLqxKLbkhOlQXmjZ7KAmRGXdcRcc9AyyDZgmmsk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":41,"rows":48},"Universidade Federal do Rio de Janeiro",[4],123,false,7,11,15566,2,96,[14,17,20,22,25,28,31,33],{"name":15,"count":16},"Healthy",9,{"name":18,"count":19},"Aging",8,{"name":21,"count":19},"Obesity",{"name":23,"count":24},"Panic Disorder",5,{"name":26,"count":27},"Insulin Resistance",4,{"name":29,"count":30},"Portal Hypertension",3,{"name":32,"count":30},"Dyslipidemia",{"name":34,"count":30},"Intensive Care Unit Acquired Weakness",[36],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07062497","Clonidine in Ultrasound-guided Rectus Sheath Block for Outpatient Umbilical Hernioplasty","2025-12-16","Rectus Sheath Block",[42,43,44,45,46,47],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[49,79,97,133,155,181,209,227,252,276,302,320,344,371,397,415,443,461,479,505,531,549,567,593,620,638,676,703,721,750,768,786,804,831,849,878,903,931,956,982],{"intervention":40,"totalTrials":50,"cells":51},1,{"EARLY_PHASE1":52,"PHASE1":55,"PHASE2":57,"PHASE3":59,"PHASE4":75,"NA":77},{"trials":53,"activeCount":54},[],0,{"trials":56,"activeCount":54},[],{"trials":58,"activeCount":54},[],{"trials":60,"activeCount":50,"soonestReadout":39},[61],{"nctId":37,"briefTitle":38,"status":62,"phases":63,"primaryCompletion":39,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":73},"RECRUITING",[44,45],"2026-04-30","2025-01-07",62,[68,69,70,71,72],"Hernia, Umbilical","Clonidine","Pain, Postoperative","Ambulatory Surgical Procedures","Regional Anesthesia Block",[40,74],"Rectus Sheath Block with Clonidine",{"trials":76,"activeCount":54},[],{"trials":78,"activeCount":54},[],{"intervention":74,"totalTrials":50,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":87,"PHASE4":93,"NA":95},{"trials":82,"activeCount":54},[],{"trials":84,"activeCount":54},[],{"trials":86,"activeCount":54},[],{"trials":88,"activeCount":50,"soonestReadout":39},[89],{"nctId":37,"briefTitle":38,"status":62,"phases":90,"primaryCompletion":39,"completion":64,"start":65,"enrollment":66,"conditions":91,"interventions":92},[44,45],[68,69,70,71,72],[40,74],{"trials":94,"activeCount":54},[],{"trials":96,"activeCount":54},[],{"intervention":98,"totalTrials":11,"cells":99},"Magnesium Sulfate",{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":131},{"trials":101,"activeCount":54},[],{"trials":103,"activeCount":54},[],{"trials":105,"activeCount":54},[],{"trials":107,"activeCount":54},[],{"trials":109,"activeCount":54},[110,122],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT02932254","Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex","COMPLETED",[46],"2017-03","2016-10",60,[119],"Neuromuscular Blockade",[98,121],"Saline",{"nctId":123,"briefTitle":124,"status":113,"phases":125,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT01828385","Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex",[46],"2013-02","2012-10",80,[119],[98,121],{"trials":132,"activeCount":54},[],{"intervention":121,"totalTrials":11,"cells":134},{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":153},{"trials":136,"activeCount":54},[],{"trials":138,"activeCount":54},[],{"trials":140,"activeCount":54},[],{"trials":142,"activeCount":54},[],{"trials":144,"activeCount":54},[145,149],{"nctId":111,"briefTitle":112,"status":113,"phases":146,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":147,"interventions":148},[46],[119],[98,121],{"nctId":123,"briefTitle":124,"status":113,"phases":150,"primaryCompletion":126,"completion":126,"start":127,"enrollment":128,"conditions":151,"interventions":152},[46],[119],[98,121],{"trials":154,"activeCount":54},[],{"intervention":156,"totalTrials":50,"cells":157},"Methimazole",{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":164,"PHASE4":166,"NA":179},{"trials":159,"activeCount":54},[],{"trials":161,"activeCount":54},[],{"trials":163,"activeCount":54},[],{"trials":165,"activeCount":54},[],{"trials":167,"activeCount":54},[168],{"nctId":169,"briefTitle":170,"status":171,"phases":172,"primaryCompletion":173,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"NCT01849861","Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone","UNKNOWN",[46],"2014-07","2014-09","2011-09",200,[15],[156],{"trials":180,"activeCount":54},[],{"intervention":182,"totalTrials":50,"cells":183},"cyclosporine and sodium carboximethycellulose",{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":207},{"trials":185,"activeCount":54},[],{"trials":187,"activeCount":54},[],{"trials":189,"activeCount":54},[],{"trials":191,"activeCount":54},[],{"trials":193,"activeCount":54},[194],{"nctId":195,"briefTitle":196,"status":171,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":205},"NCT00797030","Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus",[46],"2008-07","2008-11","2006-10",20,[203,204],"Dry Eye Syndromes","HIV Seropositivity",[182,206],"sodium carboximethycellulose",{"trials":208,"activeCount":54},[],{"intervention":206,"totalTrials":50,"cells":210},{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":225},{"trials":212,"activeCount":54},[],{"trials":214,"activeCount":54},[],{"trials":216,"activeCount":54},[],{"trials":218,"activeCount":54},[],{"trials":220,"activeCount":54},[221],{"nctId":195,"briefTitle":196,"status":171,"phases":222,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":223,"interventions":224},[46],[203,204],[182,206],{"trials":226,"activeCount":54},[],{"intervention":228,"totalTrials":50,"cells":229},"Anidulafungin",{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":250},{"trials":231,"activeCount":54},[],{"trials":233,"activeCount":54},[],{"trials":235,"activeCount":54},[],{"trials":237,"activeCount":54},[],{"trials":239,"activeCount":54},[240],{"nctId":241,"briefTitle":242,"status":113,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":249},"NCT01734525","Negative Beta Glucan in ICU Patients",[46],"2013-12","2012-11",85,[248],"Candidemia",[228],{"trials":251,"activeCount":54},[],{"intervention":253,"totalTrials":50,"cells":254},"Lopinavir\u002Fr",{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":263,"NA":274},{"trials":256,"activeCount":54},[],{"trials":258,"activeCount":54},[],{"trials":260,"activeCount":54},[],{"trials":262,"activeCount":54},[],{"trials":264,"activeCount":54},[265],{"nctId":266,"briefTitle":267,"status":113,"phases":268,"completion":269,"start":270,"enrollment":117,"conditions":271,"interventions":273},"NCT00160849","Lopinavir\u002Fr Monotherapy as Maintenance Therapy After Long Term Viral Suppression",[46],"2007-03","2004-08",[272],"HIV Infections",[253],{"trials":275,"activeCount":54},[],{"intervention":277,"totalTrials":50,"cells":278},"Clonazepam",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":300},{"trials":280,"activeCount":54},[],{"trials":282,"activeCount":54},[],{"trials":284,"activeCount":54},[],{"trials":286,"activeCount":54},[],{"trials":288,"activeCount":54},[289],{"nctId":290,"briefTitle":291,"status":113,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":298},"NCT02852577","Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine",[46],"2012-08","2000-01",120,[23,297],"Agoraphobia",[277,299],"Paroxetine",{"trials":301,"activeCount":54},[],{"intervention":299,"totalTrials":50,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":318},{"trials":305,"activeCount":54},[],{"trials":307,"activeCount":54},[],{"trials":309,"activeCount":54},[],{"trials":311,"activeCount":54},[],{"trials":313,"activeCount":54},[314],{"nctId":290,"briefTitle":291,"status":113,"phases":315,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":316,"interventions":317},[46],[23,297],[277,299],{"trials":319,"activeCount":54},[],{"intervention":321,"totalTrials":50,"cells":322},"growth hormone",{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":331,"NA":342},{"trials":324,"activeCount":54},[],{"trials":326,"activeCount":54},[],{"trials":328,"activeCount":54},[],{"trials":330,"activeCount":54},[],{"trials":332,"activeCount":54},[333],{"nctId":334,"briefTitle":335,"status":113,"phases":336,"primaryCompletion":337,"completion":337,"start":338,"enrollment":339,"conditions":340,"interventions":341},"NCT01853566","Effects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old",[46],"2013-06","2012-01",13,[15],[321],{"trials":343,"activeCount":54},[],{"intervention":345,"totalTrials":50,"cells":346},"Diacerein",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":367,"NA":369},{"trials":348,"activeCount":54},[],{"trials":350,"activeCount":54},[],{"trials":352,"activeCount":54},[],{"trials":354,"activeCount":54},[355],{"nctId":356,"briefTitle":357,"status":113,"phases":358,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":366},"NCT02242149","Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects",[45],"2017-01-31","2018-01-31","2014-10-14",84,[364,365],"Diabetes Mellitus, Type 2","Non-alcoholic Fatty Liver Disease",[345],{"trials":368,"activeCount":54},[],{"trials":370,"activeCount":54},[],{"intervention":372,"totalTrials":50,"cells":373},"Propolis tablet to limit dental biofilm",{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":393,"NA":395},{"trials":375,"activeCount":54},[],{"trials":377,"activeCount":54},[],{"trials":379,"activeCount":54},[],{"trials":381,"activeCount":54},[382],{"nctId":383,"briefTitle":384,"status":113,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":391},"NCT03394729","Effect of a Propolis Tablet on the Saliva and the Amount of Adolescent Dental Plaque Microbes",[44,45],"2020-10-21","2017-09-29",30,[390],"Dental Plaque",[372,392],"Xilytol tablet to limit dental biofilm",{"trials":394,"activeCount":54},[],{"trials":396,"activeCount":54},[],{"intervention":392,"totalTrials":50,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":411,"NA":413},{"trials":400,"activeCount":54},[],{"trials":402,"activeCount":54},[],{"trials":404,"activeCount":54},[],{"trials":406,"activeCount":54},[407],{"nctId":383,"briefTitle":384,"status":113,"phases":408,"primaryCompletion":386,"completion":386,"start":387,"enrollment":388,"conditions":409,"interventions":410},[44,45],[390],[372,392],{"trials":412,"activeCount":54},[],{"trials":414,"activeCount":54},[],{"intervention":416,"totalTrials":50,"cells":417},"Propranolol",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":439,"NA":441},{"trials":419,"activeCount":54},[],{"trials":421,"activeCount":54},[],{"trials":423,"activeCount":54},[],{"trials":425,"activeCount":54},[426],{"nctId":427,"briefTitle":428,"status":171,"phases":429,"primaryCompletion":430,"completion":431,"start":432,"enrollment":128,"conditions":433,"interventions":436},"NCT03720067","Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension",[44,45],"2020-12-20","2022-12-20","2019-01-25",[434,29,435],"Cirrhosis","Variceal Hemorrhage",[416,437,438],"Carvedilol","Rosuvastatin",{"trials":440,"activeCount":54},[],{"trials":442,"activeCount":54},[],{"intervention":437,"totalTrials":50,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":457,"NA":459},{"trials":446,"activeCount":54},[],{"trials":448,"activeCount":54},[],{"trials":450,"activeCount":54},[],{"trials":452,"activeCount":54},[453],{"nctId":427,"briefTitle":428,"status":171,"phases":454,"primaryCompletion":430,"completion":431,"start":432,"enrollment":128,"conditions":455,"interventions":456},[44,45],[434,29,435],[416,437,438],{"trials":458,"activeCount":54},[],{"trials":460,"activeCount":54},[],{"intervention":438,"totalTrials":50,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":475,"NA":477},{"trials":464,"activeCount":54},[],{"trials":466,"activeCount":54},[],{"trials":468,"activeCount":54},[],{"trials":470,"activeCount":54},[471],{"nctId":427,"briefTitle":428,"status":171,"phases":472,"primaryCompletion":430,"completion":431,"start":432,"enrollment":128,"conditions":473,"interventions":474},[44,45],[434,29,435],[416,437,438],{"trials":476,"activeCount":54},[],{"trials":478,"activeCount":54},[],{"intervention":480,"totalTrials":50,"cells":481},"Dexmedetomidine Hydrochloride",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":501,"NA":503},{"trials":483,"activeCount":54},[],{"trials":485,"activeCount":54},[],{"trials":487,"activeCount":54},[],{"trials":489,"activeCount":54},[490],{"nctId":491,"briefTitle":492,"status":171,"phases":493,"primaryCompletion":494,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":500},"NCT05489900","Immunomodulatory Effect of Dexmedetomidine as an Adjuvant Drug in Laparoscopic Cholecystectomies",[45],"2022-07-31","2022-10-31","2022-04-01",52,[499],"Physiological Effects of Drugs",[480],{"trials":502,"activeCount":54},[],{"trials":504,"activeCount":54},[],{"intervention":506,"totalTrials":50,"cells":507},"Phytolacca decandra",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":527,"NA":529},{"trials":509,"activeCount":54},[],{"trials":511,"activeCount":54},[],{"trials":513,"activeCount":54},[],{"trials":515,"activeCount":54},[516],{"nctId":517,"briefTitle":518,"status":171,"phases":519,"primaryCompletion":520,"completion":521,"start":174,"enrollment":497,"conditions":522,"interventions":524},"NCT02870543","Efficacy of Phytolacca Decandra and Melissa Officinalis in Children With Nocturnal Bruxism",[45],"2016-07","2017-07",[523],"Nocturnal Bruxism",[506,525,526],"Melissa officinalis","Phyt.decandra + Melissa offic.",{"trials":528,"activeCount":54},[],{"trials":530,"activeCount":54},[],{"intervention":525,"totalTrials":50,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":545,"NA":547},{"trials":534,"activeCount":54},[],{"trials":536,"activeCount":54},[],{"trials":538,"activeCount":54},[],{"trials":540,"activeCount":54},[541],{"nctId":517,"briefTitle":518,"status":171,"phases":542,"primaryCompletion":520,"completion":521,"start":174,"enrollment":497,"conditions":543,"interventions":544},[45],[523],[506,525,526],{"trials":546,"activeCount":54},[],{"trials":548,"activeCount":54},[],{"intervention":526,"totalTrials":50,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":563,"NA":565},{"trials":552,"activeCount":54},[],{"trials":554,"activeCount":54},[],{"trials":556,"activeCount":54},[],{"trials":558,"activeCount":54},[559],{"nctId":517,"briefTitle":518,"status":171,"phases":560,"primaryCompletion":520,"completion":521,"start":174,"enrollment":497,"conditions":561,"interventions":562},[45],[523],[506,525,526],{"trials":564,"activeCount":54},[],{"trials":566,"activeCount":54},[],{"intervention":568,"totalTrials":50,"cells":569},"Simvastatin",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":576,"PHASE4":589,"NA":591},{"trials":571,"activeCount":54},[],{"trials":573,"activeCount":54},[],{"trials":575,"activeCount":54},[],{"trials":577,"activeCount":54},[578],{"nctId":579,"briefTitle":580,"status":113,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":588},"NCT02134626","Simvastatin Effect on Portal Hypertension",[45],"2014-04","2010-08",34,[29,586,587],"Esophageal Varices","Liver Cirrhosis",[568],{"trials":590,"activeCount":54},[],{"trials":592,"activeCount":54},[],{"intervention":594,"totalTrials":50,"cells":595},"Pasireotide",{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":616,"NA":618},{"trials":597,"activeCount":54},[],{"trials":599,"activeCount":54},[],{"trials":601,"activeCount":54},[],{"trials":603,"activeCount":54},[604],{"nctId":605,"briefTitle":606,"status":113,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":614},"NCT01620138","Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas",[44,45],"2012-06","2010-03",21,[612,613],"Non-functioning Pituitary Adenomas","Prolactinomas",[594,615],"cabergoline",{"trials":617,"activeCount":54},[],{"trials":619,"activeCount":54},[],{"intervention":615,"totalTrials":50,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":634,"NA":636},{"trials":623,"activeCount":54},[],{"trials":625,"activeCount":54},[],{"trials":627,"activeCount":54},[],{"trials":629,"activeCount":54},[630],{"nctId":605,"briefTitle":606,"status":113,"phases":631,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":632,"interventions":633},[44,45],[612,613],[594,615],{"trials":635,"activeCount":54},[],{"trials":637,"activeCount":54},[],{"intervention":639,"totalTrials":11,"cells":640},"Nitazoxanide",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":642,"activeCount":54},[],{"trials":644,"activeCount":54},[],{"trials":646,"activeCount":54},[647,659],{"nctId":648,"briefTitle":649,"status":113,"phases":650,"primaryCompletion":651,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":658},"NCT04552483","Effects of Early Use of Nitazoxanide in Patients With COVID-19",[44],"2020-08-20","2020-09-05","2020-06-08",392,[656,657],"Covid19","Coronavirus",[639],{"nctId":660,"briefTitle":661,"status":113,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":669},"NCT04561219","Nitazoxanide Therapy for Patients With COVID-19 Pneumonia",[44],"2020-10-02","2020-04-19",500,[656,667,668],"Corona Virus Infection","Pneumonia, Viral",[639],{"trials":671,"activeCount":54},[],{"trials":673,"activeCount":54},[],{"trials":675,"activeCount":54},[],{"intervention":677,"totalTrials":50,"cells":678},"Methylprednisolone Arm",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":680,"activeCount":54},[],{"trials":682,"activeCount":54},[],{"trials":684,"activeCount":54},[685],{"nctId":686,"briefTitle":687,"status":688,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":54,"conditions":692,"interventions":695},"NCT01757899","Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children","WITHDRAWN",[44],"2016-01","2014-01",[693,694],"Acute Lung Injury","Acute Respiratory Distress Syndrome",[677,696],"Sterile Saline Arm",{"trials":698,"activeCount":54},[],{"trials":700,"activeCount":54},[],{"trials":702,"activeCount":54},[],{"intervention":696,"totalTrials":50,"cells":704},{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":715,"PHASE4":717,"NA":719},{"trials":706,"activeCount":54},[],{"trials":708,"activeCount":54},[],{"trials":710,"activeCount":54},[711],{"nctId":686,"briefTitle":687,"status":688,"phases":712,"primaryCompletion":690,"completion":690,"start":691,"enrollment":54,"conditions":713,"interventions":714},[44],[693,694],[677,696],{"trials":716,"activeCount":54},[],{"trials":718,"activeCount":54},[],{"trials":720,"activeCount":54},[],{"intervention":722,"totalTrials":50,"cells":723},"high Clonidine concentration",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":725,"activeCount":54},[],{"trials":727,"activeCount":54},[],{"trials":729,"activeCount":54},[730],{"nctId":731,"briefTitle":732,"status":113,"phases":733,"primaryCompletion":734,"completion":734,"start":735,"enrollment":117,"conditions":736,"interventions":740},"NCT01620112","The Effects of Different Clonidine Concentrations on Axillary Brachial Plexus Block With 1,5% Lidocaine",[44],"2011-07","2009-02",[737,738,70,739],"Fascicular Block","Motor Activity","Latency Period",[722,741,742,743],"low clonidine concentration","Lidocaine","Lidocaine 40 ml",{"trials":745,"activeCount":54},[],{"trials":747,"activeCount":54},[],{"trials":749,"activeCount":54},[],{"intervention":741,"totalTrials":50,"cells":751},{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":762,"PHASE4":764,"NA":766},{"trials":753,"activeCount":54},[],{"trials":755,"activeCount":54},[],{"trials":757,"activeCount":54},[758],{"nctId":731,"briefTitle":732,"status":113,"phases":759,"primaryCompletion":734,"completion":734,"start":735,"enrollment":117,"conditions":760,"interventions":761},[44],[737,738,70,739],[722,741,742,743],{"trials":763,"activeCount":54},[],{"trials":765,"activeCount":54},[],{"trials":767,"activeCount":54},[],{"intervention":742,"totalTrials":50,"cells":769},{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":780,"PHASE4":782,"NA":784},{"trials":771,"activeCount":54},[],{"trials":773,"activeCount":54},[],{"trials":775,"activeCount":54},[776],{"nctId":731,"briefTitle":732,"status":113,"phases":777,"primaryCompletion":734,"completion":734,"start":735,"enrollment":117,"conditions":778,"interventions":779},[44],[737,738,70,739],[722,741,742,743],{"trials":781,"activeCount":54},[],{"trials":783,"activeCount":54},[],{"trials":785,"activeCount":54},[],{"intervention":743,"totalTrials":50,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":798,"PHASE4":800,"NA":802},{"trials":789,"activeCount":54},[],{"trials":791,"activeCount":54},[],{"trials":793,"activeCount":54},[794],{"nctId":731,"briefTitle":732,"status":113,"phases":795,"primaryCompletion":734,"completion":734,"start":735,"enrollment":117,"conditions":796,"interventions":797},[44],[737,738,70,739],[722,741,742,743],{"trials":799,"activeCount":54},[],{"trials":801,"activeCount":54},[],{"trials":803,"activeCount":54},[],{"intervention":805,"totalTrials":50,"cells":806},"BCG vaccine",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":808,"activeCount":54},[],{"trials":810,"activeCount":54},[],{"trials":812,"activeCount":54},[813],{"nctId":814,"briefTitle":815,"status":171,"phases":816,"primaryCompletion":817,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":823},"NCT04659941","Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers",[44],"2022-10-01","2024-04-01","2020-10-01",752,[822],"COVID 19 Vaccine",[805,824],"0.9% sodium chloride (NaCl) saline solution",{"trials":826,"activeCount":54},[],{"trials":828,"activeCount":54},[],{"trials":830,"activeCount":54},[],{"intervention":824,"totalTrials":50,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":834,"activeCount":54},[],{"trials":836,"activeCount":54},[],{"trials":838,"activeCount":54},[839],{"nctId":814,"briefTitle":815,"status":171,"phases":840,"primaryCompletion":817,"completion":818,"start":819,"enrollment":820,"conditions":841,"interventions":842},[44],[822],[805,824],{"trials":844,"activeCount":54},[],{"trials":846,"activeCount":54},[],{"trials":848,"activeCount":54},[],{"intervention":850,"totalTrials":50,"cells":851},"Melissa",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":853,"activeCount":54},[],{"trials":855,"activeCount":54},[856],{"nctId":857,"briefTitle":858,"status":171,"phases":859,"primaryCompletion":860,"completion":861,"start":862,"enrollment":863,"conditions":864,"interventions":869},"NCT06214637","Effectiveness of Melissa Officinalis for the Treatment of Probable Sleep Bruxism in Children and Adolescents",[43],"2024-08-30","2024-09-30","2023-08-01",42,[865,866,867,868],"Sleep Bruxism","Adolescent","Children","Temporomandibular Joint Disorders",[850],{"trials":871,"activeCount":54},[],{"trials":873,"activeCount":54},[],{"trials":875,"activeCount":54},[],{"trials":877,"activeCount":54},[],{"intervention":879,"totalTrials":50,"cells":880},"Autologous bone marrow mononuclear cells",{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":882,"activeCount":54},[],{"trials":884,"activeCount":54},[885],{"nctId":886,"briefTitle":887,"status":171,"phases":888,"primaryCompletion":889,"completion":889,"start":890,"enrollment":891,"conditions":892,"interventions":894},"NCT00832247","Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis",[43],"2010-04","2009-01",15,[893],"Liver Cirrhosis Due to Virus C Chronic Hepatitis",[879],{"trials":896,"activeCount":54},[],{"trials":898,"activeCount":54},[],{"trials":900,"activeCount":54},[],{"trials":902,"activeCount":54},[],{"intervention":904,"totalTrials":50,"cells":905},"caspofungin as preemptive antifungal therapy",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":907,"activeCount":54},[],{"trials":909,"activeCount":54},[],{"trials":911,"activeCount":54},[],{"trials":913,"activeCount":54},[],{"trials":915,"activeCount":54},[],{"trials":917,"activeCount":54},[918],{"nctId":919,"briefTitle":920,"status":921,"phases":922,"primaryCompletion":923,"completion":244,"start":924,"enrollment":925,"conditions":926,"interventions":930},"NCT00982540","Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients","TERMINATED",[47],"2013-11","2010-02",28,[927,928,929],"Invasive Fungal Infections","Invasive Aspergillosis","Invasive Fusariosis",[904],{"intervention":932,"totalTrials":50,"cells":933},"Infusion of adipose tissue-derived stem\u002Fstromal cells and oral Cholecalciferol supplementation",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":935,"activeCount":54},[],{"trials":937,"activeCount":54},[],{"trials":939,"activeCount":54},[],{"trials":941,"activeCount":54},[],{"trials":943,"activeCount":54},[],{"trials":945,"activeCount":54},[946],{"nctId":947,"briefTitle":948,"status":113,"phases":949,"primaryCompletion":950,"completion":951,"start":952,"enrollment":388,"conditions":953,"interventions":955},"NCT03920397","Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus",[47],"2021-03-01","2021-05-01","2015-03-01",[954],"Type 1 Diabetes Mellitus",[932],{"intervention":957,"totalTrials":50,"cells":958},"Fish oil",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":969},{"trials":960,"activeCount":54},[],{"trials":962,"activeCount":54},[],{"trials":964,"activeCount":54},[],{"trials":966,"activeCount":54},[],{"trials":968,"activeCount":54},[],{"trials":970,"activeCount":54},[971],{"nctId":972,"briefTitle":973,"status":171,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":981},"NCT04965129","Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet",[47],"2024-05","2025-03-15","2022-11-15",50,[980],"Lung Cancer",[957],{"intervention":983,"totalTrials":50,"cells":984},"Voriconazole or posaconazole",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":986,"activeCount":54},[],{"trials":988,"activeCount":54},[],{"trials":990,"activeCount":54},[],{"trials":992,"activeCount":54},[],{"trials":994,"activeCount":54},[],{"trials":996,"activeCount":54},[997],{"nctId":998,"briefTitle":999,"status":113,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1007},"NCT02714504","Anti-mold Azole in the Prophylaxis for Invasive Fusariosis",[47],"2014-12","2008-08",239,[1005,1006],"Fusariosis","Onychomycosis",[983]]